Miron (Cilastatin, Imipenem)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Cilastatin is co‑formulated to block renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby preserving its antibacterial activity in the bloodstream.

The dosage of Miron is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Only a qualified healthcare professional should set the dosing regimen.

The safety of Miron in pregnancy and lactation has not been fully established. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To request Miron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Miron combines imipenem with cilastatin, offering a broader spectrum and enhanced renal stability compared with imipenem alone. Compared with other carbapenems such as meropenem, it has a similar spectrum but may differ in dosing frequency and susceptibility to certain beta‑lactamases, making choice dependent on local resistance patterns and clinical judgment.

Miron should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution. Do not use if the product has been exposed to temperatures outside this range.

Miron is supplied as a sterile injection for intravenous infusion. It is administered by a qualified healthcare professional, typically diluted in compatible IV fluids and infused over a prescribed period, following aseptic technique and institutional infusion protocols.

The most serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and management of these reactions are essential.

Miron is contraindicated in patients with a known hypersensitivity to imipenem, cilastatin, or any other carbapenem antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment, or previous severe allergic reactions to beta‑lactam agents.